Downregulation of miR-221 enhances the sensitivity of human oral squamous cell carcinoma cells to Adriamycin through upregulation of TIMP3 expression

Biomedicine and Pharmacotherapy

Volumn 77, Issue , 2016, Pages 72-78

  Chen, Dan ^a   Yan, Wangxiang ^a   Liu, Zhiguo ^b   Zhang, Zhaoqiang ^c   Zhu, Lijun ^d   Liu, Weidong ^a   Ding, Xueqiang ^a   Wang, Anxun ^a   Chen, Yu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Adriamycin; MiR 221; Oral squamous cell carcinoma; TIMP3

Indexed keywords

DOXORUBICIN; MICRORNA 221; TISSUE INHIBITOR OF METALLOPROTEINASE 3; ANTINEOPLASTIC ANTIBIOTIC; MICRORNA; MIRN221 MICRORNA, HUMAN; TIMP3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; UPREGULATION; GENE EXPRESSION REGULATION; GENETICS; MOUTH TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOUTH NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-3; UP-REGULATION;

EID: 84954486530     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.12.002     Document Type: Article

References (28)

1. Choi S., Myers J.N. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J. Dent. Res. 2008, 87:14-32.
2. Zini A., Czerninski R., Sgan-Cohen H.D. Oral cancer over four decades: epidemiology, trends, histology, and survival by anatomical sites. J. Oral Pathol. Med. 2010, 39:299-305.
3. Eid A., Li S., Garza R., Wong M.E. Chemotherapy for oral and maxillofacial tumors: an update. Oral Maxillofac. Surg. Clin. North Am. 2014, 26:163-169.
4. Ambros V. The functions of animal micrornas. Nature 2004, 431:350-355.
5. Bartel D.P. Micrornas: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
6. Liz J., Esteller M. Lncrnas and micrornas with a role in cancer development. Biochim. Biophys. Acta 2015, 4:00138.
7. Wang W., Zhang E., Lin C. Micrornas in tumor angiogenesis. Life Sci. 2015, 3:345-349.
8. Liu Z., Xu Y., Long J., Guo K., Ge C., Du R. Microrna-218 suppresses the proliferation, invasion and promotes apoptosis of pancreatic cancer cells by targeting hmgb1. Chin. J. Cancer Res. 2015, 27:247-257.
9. Tian K., Di R., Wang L. Microrna-23a enhances migration and invasion through pten in osteosarcoma. Cancer Gene Ther. 2015, 10:27.
10. Felli N., Fontana L., Pelosi E., Botta R., Bonci D., Facchiano F., Liuzzi F., Lulli V., Morsilli O., Santoro S., Valtieri M., Calin G.A., Liu C.G., Sorrentino A., Croce C.M., Peschle C. Micrornas 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18081-18086.
11. Nassirpour R., Mehta P.P., Baxi S.M., Yin M.J. Mir-221 promotes tumorigenesis in human triple negative breast cancer cells. PLoS One 2013, 8.
12. Liu J., Cao J., Zhao X. Mir-221 facilitates the tgfbeta1-induced epithelial-mesenchymal transition in human bladder cancer cells by targeting stmn1. BMC Urol. 2015, 15:15-28.
13. Jiang F., Zhao W., Zhou L., Liu Z., Li W., Yu D. Mir-222 targeted puma to improve sensitization of um1 cells to cisplatin. Int. J. Mol. Sci. 2014, 15:22128-22141.
14. Wei Y., Lai X., Yu S., Chen S., Ma Y., Zhang Y., Li H., Zhu X., Yao L., Zhang J. Exosomal mir-221/222 enhances tamoxifen resistance in recipient er-positive breast cancer cells. Breast Cancer Res. Treat. 2014, 147:423-431.
15. Zhao Y., Zhao L., Ischenko I., Bao Q., Schwarz B., Niess H., Wang Y., Renner A., Mysliwietz J., Jauch K.W., Nelson P.J., Ellwart J.W., Bruns C.J., Camaj P. Antisense inhibition of microrna-21 and microrna-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer. Target. Oncol. 2015, 3:3.
16. Okamoto K., Miyoshi K., Murawaki Y. Mir-29b, mir-205 and mir-221 enhance chemosensitivity to gemcitabine in huh28 human cholangiocarcinoma cells. PLoS One 2013, 8.
17. Ariyoshi Y., Shimahara M., Tanigawa N. Study on chemosensitivity of oral squamous cell carcinomas by histoculture drug response assay. Oral Oncol. 2003, 39:701-707.
18. Garcia-Contreras R., Scougall-Vilchis R.J., Contreras-Bulnes R., Ando Y., Kanda Y., Hibino Y., Nakajima H., Sakagami H. Effects of tio2 nanoparticles on cytotoxic action of chemotherapeutic drugs against a human oral squamous cell carcinoma cell line. In Vivo 2014, 28:209-215.
19. Apte S.S., Mattei M.G., Olsen B.R. Cloning of the cdna encoding human tissue inhibitor of metalloproteinases-3 (timp-3) and mapping of the timp3 gene to chromosome 22. Genomics 1994, 19:86-90.
20. Gan R., Yang Y., Yang X., Zhao L., Lu J., Meng Q.H. Downregulation of mir-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of timp3. Cancer Gene Ther. 2014, 21:290-296.
21. Garofalo M., Di Leva G., Romano G., Nuovo G., Suh S.S., Ngankeu A., Taccioli C., Pichiorri F., Alder H., Secchiero P., Gasparini P., Gonelli A., Costinean S., Acunzo M., Condorelli G., Croce C.M. Mir-221&222 regulate trail resistance and enhance tumorigenicity through pten and timp3 downregulation. Cancer Cell 2009, 16:498-509.
22. Yang C.J., Shen W.G., Liu C.J., Chen Y.W., Lu H.H., Tsai M.M., Lin S.C. Mir-221 and mir-222 expression increased the growth and tumorigenesis of oral carcinoma cells. J. Oral Pathol. Med. 2011, 40:560-566.
23. Cai K., Shen F., Cui J.H., Yu Y., Pan H.Q. Expression of mir-221 in colon cancer correlates with prognosis. Int. J. Clin. Exp. Med. 2015, 8:2794-2798.
24. Yilmaz S.S., Guzel E., Karatas O.F., Yilmaz M., Creighton C.J., Ozen M. Mir-221 as a pre- and postoperative plasma biomarker for larynx cancer patients. Laryngoscope 2015, 6:25332.
25. Wang L., Liu C., Li C., Xue J., Zhao S., Zhan P., Lin Y., Zhang P., Jiang A., Chen W. Effects of microrna-221/222 on cell proliferation and apoptosis in prostate cancer cells. Gene 2015, 9:00828.
26. Gombos K., Horvath R., Szele E., Juhasz K., Gocze K., Somlai K., Pajkos G., Ember I., Olasz L. Mirna expression profiles of oral squamous cell carcinomas. Anticancer Res. 2013, 33:1511-1517.
27. Iseri O.D., Kars M.D., Arpaci F., Gunduz U. Gene expression analysis of drug-resistant mcf-7 cells: implications for relation to extracellular matrix proteins. Cancer Chemother. Pharmacol. 2010, 65:447-455.
28. Januchowski R., Zawierucha P., Rucinski M., Nowicki M., Zabel M. Extracellular matrix proteins expression profiling in chemoresistant variants of the a2780 ovarian cancer cell line. Biomed Res. Int. 2014, 2014:365867.